WO2007138328A3 - Novel applications for staphylococcus aureus sbi protein - Google Patents
Novel applications for staphylococcus aureus sbi protein Download PDFInfo
- Publication number
- WO2007138328A3 WO2007138328A3 PCT/GB2007/002022 GB2007002022W WO2007138328A3 WO 2007138328 A3 WO2007138328 A3 WO 2007138328A3 GB 2007002022 W GB2007002022 W GB 2007002022W WO 2007138328 A3 WO2007138328 A3 WO 2007138328A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- staphylococcus aureus
- complement
- pathway
- protein
- novel applications
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2007266813A AU2007266813A1 (en) | 2006-05-31 | 2007-05-31 | Novel applications for Staphylococcus aureus Sbi protein |
EP07733038A EP2041165A2 (en) | 2006-05-31 | 2007-05-31 | Novel applications for staphylococcus aureus sbi protein |
CA002653668A CA2653668A1 (en) | 2006-05-31 | 2007-05-31 | Novel applications for staphylococcus aureus sbi protein |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0610776.7 | 2006-05-31 | ||
GB0610776A GB0610776D0 (en) | 2006-05-31 | 2006-05-31 | Novel applications for staphylococcus aureus Sbi protein |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007138328A2 WO2007138328A2 (en) | 2007-12-06 |
WO2007138328A3 true WO2007138328A3 (en) | 2008-05-08 |
Family
ID=36694713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2007/002022 WO2007138328A2 (en) | 2006-05-31 | 2007-05-31 | Novel applications for staphylococcus aureus sbi protein |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2041165A2 (en) |
AU (1) | AU2007266813A1 (en) |
CA (1) | CA2653668A1 (en) |
GB (1) | GB0610776D0 (en) |
WO (1) | WO2007138328A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008214359B2 (en) * | 2007-02-05 | 2014-01-16 | Apellis Pharmaceuticals, Inc. | Local complement inhibition for treatment of complement-mediated disorders |
US8592555B2 (en) | 2008-08-11 | 2013-11-26 | Emd Millipore Corporation | Immunoglobulin-binding proteins with improved specificity |
SG195555A1 (en) | 2008-12-24 | 2013-12-30 | Emd Millipore Corp | Caustic stable chromatography ligands |
GB201016403D0 (en) * | 2010-09-29 | 2010-11-10 | Bath Ventures | Novel interaction between staphylococcus aureus Sbi and C3d protiens |
WO2012095519A1 (en) * | 2011-01-13 | 2012-07-19 | Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie | Potent inhibitors of complement activation |
SG186552A1 (en) * | 2011-06-08 | 2013-01-30 | Emd Millipore Corp | Chromatography matrices including novel staphylococcus aureus protein a based ligands |
WO2013142349A1 (en) * | 2012-03-23 | 2013-09-26 | University Of Chicago | Compositions and methods related to staphylococcal sbi |
GB201619965D0 (en) | 2016-11-25 | 2017-01-11 | Univ Of Bath The | Immunogenic compositions comprising sbi protein and uses thereof |
JP2024508683A (en) | 2021-03-04 | 2024-02-28 | ヘリックス ナノテクノロジーズ, インコーポレイテッド | Compositions containing SBI adjuvants and methods of use thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999024467A1 (en) * | 1997-11-12 | 1999-05-20 | Biostapro Ab | IgG-BINDING PROTEIN FROM STAPHYLOCOCCUS AND NUCLEOTIDE SEQUENCE ENCODING THIS PROTEIN |
WO2002059148A2 (en) * | 2001-01-26 | 2002-08-01 | Intercell Ag | A method for identification, isolation and production of antigens to a specific pathogen |
WO2003011899A2 (en) * | 2001-08-02 | 2003-02-13 | University Of Sheffield | Antigenic polypeptides |
WO2006032472A2 (en) * | 2004-09-22 | 2006-03-30 | Glaxosmithkline Biologicals S.A. | Immunogenic composition for use in vaccination against staphylococcei |
WO2007071692A2 (en) * | 2005-12-21 | 2007-06-28 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
-
2006
- 2006-05-31 GB GB0610776A patent/GB0610776D0/en not_active Ceased
-
2007
- 2007-05-31 AU AU2007266813A patent/AU2007266813A1/en not_active Abandoned
- 2007-05-31 EP EP07733038A patent/EP2041165A2/en not_active Withdrawn
- 2007-05-31 WO PCT/GB2007/002022 patent/WO2007138328A2/en active Application Filing
- 2007-05-31 CA CA002653668A patent/CA2653668A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999024467A1 (en) * | 1997-11-12 | 1999-05-20 | Biostapro Ab | IgG-BINDING PROTEIN FROM STAPHYLOCOCCUS AND NUCLEOTIDE SEQUENCE ENCODING THIS PROTEIN |
WO2002059148A2 (en) * | 2001-01-26 | 2002-08-01 | Intercell Ag | A method for identification, isolation and production of antigens to a specific pathogen |
WO2003011899A2 (en) * | 2001-08-02 | 2003-02-13 | University Of Sheffield | Antigenic polypeptides |
WO2006032472A2 (en) * | 2004-09-22 | 2006-03-30 | Glaxosmithkline Biologicals S.A. | Immunogenic composition for use in vaccination against staphylococcei |
WO2007071692A2 (en) * | 2005-12-21 | 2007-06-28 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
Non-Patent Citations (5)
Title |
---|
LEE LAWRENCE Y L ET AL: "Identification and characterization of the C3 binding domain of the Staphylococcus aureus extracellular fibrinogen-binding protein (Efb)", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 49, 3 December 2004 (2004-12-03), pages 50710 - 50716, XP002465564, ISSN: 0021-9258 * |
SAHU A ET AL: "Structure and biology of complement protein C3, a connecting link between innate and acquired immunity", IMMUNOLOGICAL REVIEWS, MUNKSGAARD, vol. 180, April 2001 (2001-04-01), pages 35 - 48, XP002962792, ISSN: 0105-2896 * |
WILLIAM T MORGAN: "Encyclopedia of Molecular Medicine, Volumes 1-5", 2002, JOHN WILEY & SONS, INC., XP002465565 * |
ZHANG L ET AL: "A SECOND IGG-BINDING PROTEIN IN STAPHYLOCOCCUS AUREUS", MICROBIOLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, READING, GB, vol. 144, 1998, pages 985 - 991, XP001084184, ISSN: 1350-0872 * |
ZHANG L ET AL: "Staphylococcus aureus expresses a cell surface protein that binds both IgG and beta2-glycoprotein I", MICROBIOLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, READING, GB, vol. 145, no. PART 1, January 1999 (1999-01-01), pages 177 - 183, XP002442501, ISSN: 1350-0872 * |
Also Published As
Publication number | Publication date |
---|---|
GB0610776D0 (en) | 2006-07-12 |
EP2041165A2 (en) | 2009-04-01 |
CA2653668A1 (en) | 2007-12-06 |
AU2007266813A1 (en) | 2007-12-06 |
WO2007138328A2 (en) | 2007-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007138328A3 (en) | Novel applications for staphylococcus aureus sbi protein | |
WO2008061724A3 (en) | Compositions comprising carnosic acid 12-methylether | |
NO20084024L (en) | Imidazole-based compounds, preparations comprising them, and their use | |
WO2008051416A3 (en) | Compounds that inhibit the activity of hsp90 for treating infections | |
WO2010151799A3 (en) | Compounds for modulating rna binding proteins and uses therefor | |
WO2008064018A8 (en) | Thienopyrimidinones for treatment of inflammatory disorders and cancers | |
WO2009043889A3 (en) | Oxadiazole derivatives | |
WO2008067219A3 (en) | Quinazolinone modulators of tgr5 | |
WO2007040650A3 (en) | Apoptosis promoters | |
WO2008019124A8 (en) | Heteroaryl compounds useful as inhibitors of e1 activating enzymes | |
WO2010151797A3 (en) | Compounds for modulating rna binding proteins and uses therefor | |
WO2008070129A3 (en) | Compositions and methods for the treatment of inflammatory disease | |
MX2009000285A (en) | Substituted piperidines that increase p53 activity and the uses thereof. | |
AU2006254902A8 (en) | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway | |
WO2008002571A3 (en) | Human protein tyrosine phosphatase inhibitors and methods of use | |
EP2647692A3 (en) | Compositions and methods comprising serine protease variants | |
WO2008060374A3 (en) | Methods and compositions useful for diabetic wound healing | |
ATE495743T1 (en) | TRIAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF DEGENERATIONAL AND INFLAMMATORY DISEASES | |
WO2008033562A3 (en) | Kinase inhibitor compounds | |
WO2007022225A3 (en) | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof | |
WO2006113919A3 (en) | Aryl alkyl acid derivatives for and use thereof | |
WO2009155001A3 (en) | Wnt protein signalling inhibitors | |
WO2007095601A3 (en) | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome | |
WO2007009120A3 (en) | Heterotetracyclic compounds as tpo mimetics | |
WO2007084162A3 (en) | Sirtuin inhibiting compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07733038 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2653668 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 573249 Country of ref document: NZ Ref document number: 2007266813 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007733038 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2007266813 Country of ref document: AU Date of ref document: 20070531 Kind code of ref document: A |